Literature DB >> 2577429

Recovery of renal function in patients treated by CAPD.

J Rottembourg1, B Issad, M Allouache, C Jacobs.   

Abstract

Recovery of renal function was observed in 10 out of 300 patients (3.3%) treated by CAPD. These 10 patients presented the following primary renal diseases: 4 nephroangiosclerosis, 4 interstitial nephropathies, 1 diabetic nephropathy, 1 unknown nephropathy, and were treated by CAPD for a mean period of 10.2 +/- 5.5 months. CAPD was discontinued when residual renal function reached 12 ml/min. After recovery 8 patients were still alive, including 1 patient who returned to dialysis. 2 patients died. When risk factors such as uncontrolled hypertension, cardiac failure, severe nephrotic syndrome, rapidly progressive renal failure, analgesics or non steroidal anti-inflammatory drug treatments or abuses, chronic urinary obstruction, cholesterol emboli were associated with end stage renal failure, CAPD should be the dialysis treatment of choice, expecting the preservation of the kidney capacities and further a recovery of renal function.

Entities:  

Mesh:

Year:  1989        PMID: 2577429

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  3 in total

1.  Possible factors contributing to similar peritoneal dialysis outcome in patients over 60 years of age and the younger ones.

Authors:  Alicja E Grzegorzewska; Magdalena Leander
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Recovery of kidney function after dialysis initiation in children and adults in the US: A retrospective study of United States Renal Data System data.

Authors:  Elaine Ku; Raymond K Hsu; Kirsten L Johansen; Charles E McCulloch; Mark Mitsnefes; Barbara A Grimes; Kathleen D Liu
Journal:  PLoS Med       Date:  2021-02-19       Impact factor: 11.069

3.  Modified Peritoneal Dialysis Catheter Insertion: Comparison with a Conventional Method.

Authors:  Yong Kyu Lee; Pil-Sung Yang; Kyoung Sook Park; Kyu Hun Choi; Beom Seok Kim
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.